Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy

This publication has 31 references indexed in Scilit:

• Interstrand crosslink repair: can XPF-ERCC1 be let off the hook?
  Trends in Genetics, 2008
• Contributions of DNA interstrand cross-links to aging of cells and organisms
  Nucleic Acids Research, 2007
• BRCA1: A Novel Prognostic Factor in Resected Non-Small-Cell Lung Cancer
  PLOS ONE, 2007
• The ERCC1/XPF endonuclease is required for efficient single-strand annealing and gene conversion in mammalian cells
  Nucleic Acids Research, 2007
• Double-strand breaks induce homologous recombinational repair of interstrand cross-links via cooperation of MSH2, ERCC1-XPF, REV3, and the Fanconi anemia pathway
  DNA Repair, 2007
• A Phase I, Randomized, Open-Label, Parallel-Cohort, Dose-Finding Study of Elacridar (GF120918) and Oral Topotecan in Cancer Patients
  Clinical Cancer Research, 2007
• DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy
  New England Journal of Medicine, 2006
• Overexpression of cMOAT (MRP2/ABCC2) Is Associated with Decreased Formation of Platinum-DNA Adducts and Decreased G2-Arrest in Melanoma Cells Resistant to Cisplatin
  Journal of Investigative Dermatology, 2003
• Topoisomerase IIα and other drug resistance markers in advanced non-small cell lung cancer
  Lung Cancer, 2001
• Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo.
  The Journal of Experimental Medicine, 1996